Pharmaceutical compositions for treating ocular diseases or disorders

1 . A pharmaceutical composition for treating an ocular disease or disorder, comprising:

(a) a biodegradable polymer matrix consisting of a mixture of a first polymer and a second polymer, wherein:

(1) the first polymer is a biodegradable polyester amide polymer, wherein the biodegradable polyester amide polymer comprises structure (II):

and

(2) the second polymer is a combination of an ester end-capped biodegradable poly (D,L-lactide-co-glycolide) copolymer and an acid end-capped biodegradable poly (D,L-lactide-co-glycolide) copolymer; and

(b) at least one therapeutic agent, pharmaceutically acceptable salt, zwitterion, polymorph, or solvate thereof, wherein the at least one therapeutic agent is selected from gefitinib, lapatinib, erlotinib, sunitinib, sorafenib, regorafenib, afatinib, vandetanib, semaxanib, cediranib, neratinib, axitinib, lestaurtinib, tivozanib, dexamethasone, or (1R,2R)—N-(4-methylisoquinolin-6-yl)-2-(4-(N-(pyridin-2-yl)sulfamoyl)phenyl)cyclopropane-1-carboxamide;

wherein the at least one therapeutic agent, pharmaceutically acceptable salt, zwitterion, polymorph, or solvate thereof is homogenously dispersed within the biodegradable polymer matrix;

wherein the pharmaceutical composition is formulated for intravitreal administration to a subject's eye, and the pharmaceutical composition is formulated to release the at least one therapeutic agent from the pharmaceutical composition in a substantially linear manner for at least 6 months;

wherein the biodegradable polymer matrix is about 59 weight % of the pharmaceutical composition, and the at least one therapeutic agent, pharmaceutically acceptable salt, zwitterion, polymorph, or solvate thereof is about 41 weight % of the pharmaceutical composition; and

wherein the first polymer is about 60 weight % of the biodegradable polymer matrix and the second polymer is about 40 weight % of the biodegradable polymer matrix.

2 . A pharmaceutical composition as in claim 1 , wherein the at least one therapeutic agent is selected from:

gefitinib;

lapatinib;

erlotinib;

sunitinib;

sorafenib;

regorafenib;

afatinib;

vandetanib;

semaxanib;

cediranib;

neratinib;

axitinib;

lestaurtinib;

tivozanib; or

a combination thereof.

3 . A pharmaceutical composition as in claim 1 , wherein the biodegradable polymer matrix is a mechanical blend of the first polymer and the second polymer.

4 . A pharmaceutical composition as in claim 1 , wherein:

the ester end-capped biodegradable poly (D,L-lactide-co-glycolide) copolymer is about 20 weight % of the biodegradable polymer matrix, and the acid end-capped biodegradable poly (D,L-lactide-co-glycolide) copolymer is about 20 weight % of the biodegradable polymer matrix.

5 . A pharmaceutical composition as in claim 1 , wherein the pharmaceutical composition is a particle comprising dimensions of about 200×200×4500 μm.